Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism
Abatacept outperformed hydroxychloroquine (HCQ) in preventing patients with palindromic rheumatism (PR) from progressing to rheumatoid arthritis (RA).
METHODOLOGY:
Researchers randomly assigned 70 individuals with PR who were seropositive for rheumatoid factor or anti-citrullinated protein antibodies in a 1:1 ratio to receive open-label abatacept (ABA) at 125 mg/week or HCQ at 5 mg/kg/day for 1 year.
All patients had symptom durations of over 3 months but under 3 years and were not taking any disease-modifying antirheumatic drugs or glucocorticoids.
Patients were followed for an additional year to track RA development.
TAKEAWAY:
At month 24, three patients (8.8%) in the ABA group progressed to RA compared with 10 patients (27.8%) in the HCQ group (P = .047).
Patients treated with HCQ who developed RA generally progressed in the first 12 months of the trial, whereas patients treated with ABA who developed RA did so at the end of the second year.
The ABA group also had higher persistent remission rates of PR than the HCQ group (55.9% vs 22.9%).
Serious adverse events were uncommon in both treatment groups.
IN PRACTICE:
'In patients with recent-onset seropositive palindromic rheumatism, abatacept significantly decreased the rate of RA progression in comparison with hydroxychloroquine at 2 years follow-up,' said study author Raimon Sanmarti, MD, PhD, of the Hospital Clínic de Barcelona, Barcelona, Spain. 'Abatacept is also more efficacious than hydroxychloroquine in the control of symptoms of seropositive palindromic rheumatism.'
SOURCE:
Sanmarti presented the study in an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting.
LIMITATIONS:
This was an open-label study with a relatively small sample of patients. Over the 2-year trial, eight patients in the HCQ group and five patients in the ABA group exited the trial or were lost to follow-up.
DISCLOSURES:
The Fundació Clínic per a la Recerca Biomèdica sponsored the study. Sanmarti disclosed financial relationships with Bristol Myers Squibb, AbbVie, MSD, Roche, UCB, Pfizer, Eli Lilly, Gebro, Janssen, Sanofi, Gilead, and Adacyte.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models. The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio. AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes. By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed. Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.' In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor. "Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
What a new study suggests about pregnancy diet and type 1 diabetes—and why it's not about being perfect
It's not about being perfect—it's about having the tools to make informed choices. When you're pregnant, it can feel like everything comes with a warning label. And now, a new study adds another layer to the conversation—this time linking a mom's diet during pregnancy to the risk of type 1 diabetes in her child. But before this sparks anxiety over your last bite of pizza or bowl of pasta, let's take a breath—and break down what this research actually means for you and your baby. Because while the study's findings are significant, they aren't meant to shame—they're meant to empower. It's not about being perfect. It's about having the tools to make informed choices. Researchers behind a large-scale Danish study, published in the Journal of Epidemiology & Community Health, analyzed data from more than 67,000 mother-child pairs over a 17-year period. They discovered that when pregnant women ate diets higher in inflammation-promoting foods—like processed meats, sugary drinks, and refined carbs—their children were observed to have a 16% higher risk of developing type 1 diabetes for every one-point increase in the diet's inflammatory score. This does not mean the diet caused diabetes, only that a pattern was observed. This dietary score, called the EDII (Empirical Dietary Inflammatory Index), was calculated using food frequency questionnaires filled out around 25 weeks into pregnancy. Type 1 diabetes is an autoimmune condition—often diagnosed in childhood—where the immune system mistakenly attacks the body's insulin-producing cells. While genetics play a role, the rising number of cases in developed countries suggests that environmental factors, including prenatal exposures, may also be at play. The study also found that high gluten intake and maternal smoking during mid-pregnancy were independently associated with increased diabetes risk in children—pointing to this stage of pregnancy as a potentially critical window for fetal immune development. Related: New study: Cutting sugar in the first 1,000 days could shape your baby's health for life 'Inflammatory' doesn't just mean sugary foods. In this study, higher EDII scores were associated with frequent intake of: Processed or red meats Refined grains (like white bread and pastries) Fried foods Sugary beverages Foods containing trans fats In contrast, lower EDII scores—indicating a more anti-inflammatory diet—were linked to greater consumption of: Leafy greens and cruciferous vegetables Garlic and tomatoes Fruits and whole grains Coffee and tea These food patterns closely resemble the Mediterranean diet, long celebrated for its role in supporting heart health and reducing chronic inflammation. Related: Eating a Mediterranean diet could increase your chances of becoming pregnant, studies show It's easy to read a study like this and feel an onslaught of food guilt. But here's the reality: this isn't about moral judgment—it's about informed awareness. It's also important to remember that many parents whose children develop type 1 diabetes followed healthy or typical diets. Autoimmune conditions are complex, and no one decision during pregnancy can guarantee or prevent an outcome.' Importantly, the researchers emphasized that their findings are observational—meaning they show associations, not direct cause-and-effect. Still, the patterns were strong enough to suggest that diet during mid-pregnancy may have a meaningful influence on the developing immune system. So what can you do with this information? You don't need to toss your cravings out the window or obsess over every ingredient. Instead, you can take small, sustainable steps that feel good to you and your body. If you're pregnant (or planning to be), consider these realistic, non-restrictive shifts: Add before you subtract. Focus on including more fiber-rich, whole foods before worrying about cutting things out. Make swaps where it feels easy. Choose brown rice or quinoa instead of white rice; opt for olive oil instead of butter when you can. Don't stress over every meal. It's what you do most of the time—not all of the time—that matters. Small shifts count. If access to fresh produce or high-quality ingredients is limited, know that every small shift still counts. Frozen vegetables, canned beans, or even simple substitutions like whole-grain bread are powerful steps. Ask for support. A registered dietitian or your OB-GYN can help you personalize your approach based on your cravings, health needs, and energy levels. This study doesn't mean that every food decision during pregnancy needs to be scrutinized or optimized. It means that we're learning more—and that knowledge can be powerful. Especially when it comes from a place of support, not shame. By understanding how inflammation works and how certain foods may influence a child's risk of developing autoimmune conditions like type 1 diabetes, moms can feel more confident making the choices that are right for them. If you're learning this after your pregnancy—or after a diagnosis—it's never too late to apply that knowledge in ways that support your child or future pregnancies. Growth is a sign of strength, not regret. Because you deserve to feel informed, supported—and never judged—for doing the best you can with the knowledge you have. Source: Journal of Epidemiology & Community Health. 2025. 'Association between a pro-inflammatory dietary pattern during pregnancy and type 1 diabetes risk in offspring: prospective cohort study'
Yahoo
2 hours ago
- Yahoo
Popular weight-loss drugs show promising new power against debilitating migraines
Beyond diabetes control and weight management, GLP-1s could have yet another benefit: helping with migraines. In a small study, a GLP-1 drug shrank the number of days people spent with a migraine by almost half in a given month. Presented at the European Academy of Neurology Congress in Helinski, Finland, on June 21, the results suggest promising future uses of the popular obesity and diabetes drugs. Who Should Be Taking Weight-loss Drugs? Doctors Share Best Candidates Nearly 40 million Americans deal with migraines, according to the World Health Organization (WHO) — and for many, they're more than just a headache. Migraines are the second-leading cause of disability worldwide, the above agency states, with symptoms including severe headaches, nausea and sensitivity to light often disrupting daily activities. Read On The Fox News App Previous studies have shown that GLP-1s can reduce pressure inside the skull, which is a possible cause of migraines, according to multiple health organizations. Neurologist and study lead Simone Braca of the University of Naples Federico II in Italy, along with his colleagues, explored whether liraglutide, an earlier version of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), could help migraine sufferers. Thirty-one adults, 26 of them women, got daily injections of liraglutide for 12 weeks. The participants, who all met the criteria for obesity, also continued to take their current migraine medications. At the start of the experiment, participants reported headaches about 20 days out of a month. After 12 weeks of liraglutide, the average number dropped to about 11 days. "Most patients felt better within the first two weeks and reported quality of life improved significantly," said Braca in a press release for the study, which was published in the journal Headache last month. The relief from migraines lasted for the full three-month observation period, the researcher noted, although weight loss was "modest and statistically non-significant." Participants' weight stayed about the same during the trial, suggesting that the headache reductions weren't tied to weight loss. Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds "Liraglutide is a 'middle-aged' GLP-1, with Ozempic and Mounjaro being newer," Dr. Sue Decotiis, a triple board-certified weight loss specialist in New York City, told Fox News Digital. Decotiis, who was not involved in the study, said that liraglutide is not as effective as its newer cousins for weight loss or diabetes, and is not frequently used for these purposes. "Many pharmacies are not even stocking it due to declining demand, yet it gets into the brain well enough to reduce migraines," she noted. The trial didn't include a comparison group, and participants and researchers all knew that everyone received liraglutide, the researchers noted. Mild gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants, but did not lead to treatment discontinuation. Further research may include other groups, such as control groups and people without obesity, to compare the drug's effects. "The study was very small," Decotiis confirmed to Fox News Digital. Given its size and brief duration, the findings could be limited until further research is conducted, according to the expert. Click Here To Sign Up For Our Health Newsletter The researchers also tested only one drug, liraglutide, "which is not used as frequently in the general population as semaglutide or tirzepatide are," Decotiis added. For more Health articles, visit Next, the team is planning a randomized, double-blind trial that will also measure pressure inside the skull. "We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects," Braca said in the same press article source: Popular weight-loss drugs show promising new power against debilitating migraines
